Predictive value of soluble haemoglobin scavenger receptor CD163 serum levels for survival in verified tuberculosis patients

Pre-treatment serum levels of sCD163 were measured in a cohort of 236 suspected tuberculosis (TB) cases from Guinea-Bissau, with a median follow-up period of 3.3 years (range 0–6.4 years). In 113 cases, the diagnosis of TB was verified by positive sputum microscopy and/or culture. Among the verified...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical microbiology and infection Vol. 11; no. 9; pp. 730 - 735
Main Authors:	Knudsen, T.B., Gustafson, P., Kronborg, G., Kristiansen, T.B., Moestrup, S.K., Nielsen, J.O., Gomes, V., Aaby, P., Lisse, I., Møller, H.J., Eugen-Olsen, J.
Format:	Journal Article
Language:	English
Published:	Oxford, UK Elsevier Ltd 01-09-2005 Blackwell Science Ltd Blackwell
Subjects:	Adult Antigens, CD - blood Antigens, Differentiation, Myelomonocytic - blood Bacterial diseases Basic Medicine Biological and medical sciences Biomarkers - blood CD163 Cohort Studies Disease Progression Disease-Free Survival Female Human bacterial diseases human immunodeficiency virus Human immunodeficiency virus 1 Human immunodeficiency virus 2 Humans Infectious diseases Male Medical and Health Sciences Medical sciences Medicin och hälsovetenskap Medicinska och farmaceutiska grundvetenskaper Microbiology in the medical area Mikrobiologi inom det medicinska området Mycobacterium Mycobacterium tuberculosis prognostic marker Receptors, Cell Surface - blood survival Treatment Outcome tuberculosis Tuberculosis and atypical mycobacterial infections Tuberculosis, Pulmonary - blood Tuberculosis, Pulmonary - complications Tuberculosis, Pulmonary - diagnosis Tuberculosis, Pulmonary - drug therapy human immunodeficiency virus CD163 prognostic marker survival tuberculosis Human Prognosis Retroviridae Mycobacterial infection Lentivirus Survival Infection Virus Tuberculosis Bacteriosis Predictive value Serum Human immunodeficiency virus
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Pre-treatment serum levels of sCD163 were measured in a cohort of 236 suspected tuberculosis (TB) cases from Guinea-Bissau, with a median follow-up period of 3.3 years (range 0–6.4 years). In 113 cases, the diagnosis of TB was verified by positive sputum microscopy and/or culture. Among the verified TB cases, a decreased survival rate was found in 27 patients with sCD163 levels above the upper reference limit (3.95 µg/mL). The difference in survival was significant during TB treatment (log rank, p < 0.02) and after long-term follow-up (log rank, p < 0.001). The decrease in survival rate during TB treatment remained significant in a multivariate Cox model controlling for human immunodeficiency virus (HIV) status, age and gender, with a mortality increase of 1.19 (95% CI, 1.04–1.36) per µg of sCD163, and a hazard ratio (HR) for sCD163 levels above the upper reference limit of 4.18 (95% CI, 1.06–16.4). The difference was not significant after excluding patients with concomitant HIV-1 and HIV-2 infection in Kaplan–Meier analyses (log rank, p 0.11). In contrast, the difference in survival remained significant in Kaplan–Meier analyses after long-term follow-up, even after excluding patients with concomitant HIV-1 and HIV-2 infection (log rank, p 0.002). In the Cox model, the mortality increase per µg of sCD163 was 1.27 (95% CI, 1.14–1.40), with an HR for elevated sCD163 levels of 2.85 (95% CI, 1.44–5.63). The HRs for concomitant HIV-1 and HIV-2 infection were 6.92 (95% CI, 3.28–14.58) and 2.48 (95% CI, 1.09–5.67), respectively. Thus, sCD163 levels appeared to be an independent predictor of survival in verified TB patients.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1198-743X 1469-0691 1469-0691
DOI:	10.1111/j.1469-0691.2005.01229.x